JPRN-jRCT2080220267未知3 期
An Open, Phase III, Multicentre, 52-Week Study, Evaluating the Safety and Efficacy of Symbicort Turbuhaler (1, 2, and 4 x 160/4.5ug Twice Daily) in Japanese Patients With Asthma
适应症
试验速览
- 阶段
- 3 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 16age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Ages Eligible for Study: 16 Years and above
- •Genders Eligible for Study: Both
- •Inclusion Criteria:
- •- Diagnosis of asthma with a documented history of at least 6 months duration prior to Visit 1
- •- Prescribed daily use of an IGCS for =12 weeks prior to Visit 1
- •- Prescribed daily use of at least one of the following:
- •Theophylline, long acting beta2-agonist (LABA), other anti-asthmatic drugs (leucotrine antagonists, inhaled anti-cholinergics, Th2 cytokine inhibitor) for at least 4 weeks prior to Visit 1 at a constant dose
排除标准
- •- Any significant disease or disorder that may jeopardize the safety of the patient
- •- Respiratory infection, judged by the investigator(s) as an infection affecting the asthma, within 4 weeks prior to Visit 1
- •- Treatment with oral, parenteral or rectal GCS within 4 weeks prior to Visit 1
研究者
相似试验
进行中（未招募）
1 期
A Phase III, Multicenter, 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Efficacy and Safety of ICA-17043 with or without Hydroxyurea Therapy in Patients with Sickle Cell Disease who have had = 2 Acute Sickle-Related Painful Crises within the Preceding 12 Months. - A Stratified Sickle Event Randomised Trial - ASSERTSickle Cell DiseaseEUCTR2004-004617-42-GBIcagen Inc328
进行中（未招募）
1 期
A Study of Ixekizumab in Participants With Active Psoriatic ArthritisArthritic PsoriasisMedDRA version: 18.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 100000004859EUCTR2015-002433-22-GBEli Lilly and Company400
进行中（未招募）
1 期
A Study of Ixekizumab in Participants With Active Psoriatic ArthritisEUCTR2015-002433-22-ESEli Lilly and Company400
进行中（未招募）
1 期
A Study of Ixekizumab in Participants With Active Psoriatic ArthritisArthritic PsoriasisMedDRA version: 18.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2015-002433-22-SKEli Lilly and Company400
进行中（未招募）
1 期
A Study of Ixekizumab in Participants With Active Psoriatic ArthritisEUCTR2015-002433-22-CZEli Lilly and Company400